Abbott’s Michigan Baby Formula plant has resumed production after a long hiatus

Abbott’s Michigan Baby Formula plant has resumed production after a long hiatus

Michigan’s Abbott Nutrition Factory resumes production of baby formula, which was shut down in February due to contamination For a national lackA company spokesman said.

Damage from severe thunderstorms, including floods, forced the stargis plant Stop operations in mid-JuneJust two weeks later Production is being resumed Including additional sanitizing and security protocols.

Abbott spokesman John Koval said Elecare’s production, a special formula for children with severe food allergies and indigestion problems, was recovered after a July 1 reboot in Sturgeon.

“We are working to restart Similac production as soon as possible. We will provide more information once we receive it,” he said via email.

Abbott withdrew formulas from several top brands, including Similac, in February. The supply chain is already under pressure due to supply chain disruption and stockpiling during the Covid-19 shutdown.

Since the beginning of April, chains like Walgreens, CVS and Target have limited how many baby formula products can be purchased at once. According to the data assemblies at the time, 40% to 50% of baby formula products were out of stock in 26 states.

The deficiency was most severe for children with allergies, digestive problems and metabolic disorders who relied on special formulas.

President Joe Biden’s administration has since relaxed import rules for foreign manufacturers, introduced airlift formulas from Europe and federal emergency rules to prioritize U.S. manufacturing.

Abbott is just one of four companies that produce about 90% of U.S. formulas. Koval declined to say how much of Abbott’s overall U.S. supply of baby formula was produced at the Sturges plant.

The plant was shut down in February after the Food and Drug Administration began investigating four bacterial infections in children receiving powder formula from the plant. Two children died. The company said its products were not directly linked to the infection, which involved various bacterial strains.

FDA inspectors have finally uncovered a number of violations, including bacterial contamination at the plant, a leaking roof and loose protection protocols.

With the discovery of COVID-19 in the United States in early 2020, the FDA pulled most of its safety inspectors off the field, avoiding thousands of regular plant inspections.

On Wednesday, the Food and Drug Administration announced plans to help foreign manufacturers who have shipped supplies, to meet deficits under emergency approval, to secure long-term approval to market their formulas in the United States to supply American consumers. Make more choices and supplies more resilient against current or future shortages.

FDA Commissioner Dr. Robert Calif and Susan Maine, director of the agency’s Center for Food Safety and Applied Nutrition, said in a statement that the shutdown of the Stargis plant “has shown how weak the supply chain has become due to unforeseen natural weather events.”

Leave a Reply

Your email address will not be published.